

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231.
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/421,213	10/20/1999	TIMOTHY J. O'BRIEN	D6064CIP	3804
27851 75	90 . 11/26/2001			
BENJAMIN A. ADLER			EXAMINER	
8011 CANDLE HOUSTON, TX			, HARRIS, ALANA M	
			ART UNIT	PAPER NUMBER
			1642	18
			DATE MAILED: 11/06/2001 / 0	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No. Applicant(s)					
Advisory Action	09/421,213	O'BRIEN ET AL.				
Autreory Medicin	Examiner	Art Unit				
	Alana M. Harris, Ph.D.	1642	:			
The MAILING DATE of this communication app	ars on the cover sheet with the c	correspondence address				
THE REPLY FILED 25 September 2001 FAILS TO PLA Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this applice I) a timely filed amendment whi	cation. A proper reply to a ch places the application i	n nued			
PERIOD FOR RE	PLY [check either a) or b)]		They.			
a) The period for reply expires <u>3</u> months from the mailing date of	•	· _				
b) The period for reply expires on: (1) the mailing date of this Adv event, however, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).	an SIX MONTHS from the mailing date of	f the final rejection.				
Extensions of time may be obtained under 37 CFR 1.136(a). The dat have been filed is the date for purposes of determining the period of extens 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three mo earned patent term adjustment. See 37 CFR 1.704(b).	sion and the corresponding amount of the I statutory period for reply originally set in	fee. The appropriate extension fe the final Office action; or (2) as se	e under t forth in uce any			
1 A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFR			The fee			
$2. \boxtimes$ The proposed amendment(s) will not be entered be	ecause:					
(a) X they raise new issues that would require further	er consideration and/or search (see NOTE below);				
(b) ⊠ they raise the issue of new matter (see Note below);						
(c) they are not deemed to place the application i issues for appeal; and/or	n better form for appeal by mat	erially reducing or simplify	ingsthe			
(d) \square they present additional claims without cancel	ing a corresponding number of	finally rejected claims.				
NOTE: <u>See Continuation Sheet</u> .						
3. Applicant's reply has overcome the following reject	tion(s):					
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s)	be allowable if submitted in a s	separate, timely filed amen	dment			
5. The a) affidavit, b) exhibit, or c) request fo application in condition for allowance because:		sidered but does NOT plac	e the			
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were new	ly			
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we	ould be rejected is provided below					
The status of the claim(s) is (or will be) as follows:		SIV O CABUTA	×. 1.			
Claim(s) allowed:		(NY C. CAPUTA RY PATENT EXAMMER	*/ 1/			
Claim(s) objected to:		OGY CENTER 1600				
Claim(s) rejected: <u>22-24</u> .						
Claim(s) withdrawn from consideration:						
8. The proposed drawing correction filed on is						
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
10. Other:		•				
			٠.			

 $\hat{t}_{i,j}^{(2)}$

 $\mathcal{J}_{k,n}^{(i)}\mathcal{J}_{k}$

 ${\bf q}_{i_{1},i_{1}}$

Continuation of 2. NOTE: There is no evidence within the specification that supports Applicants amendments to claims 22 and 24. These claim amendments if entered would present new matter added to the claims and would the claims would require anew search. Furthermore, there is no support in the disclosure that suggests that Applicants contemplated antibodies to specific domains of the TADG-15 protein defined as SEQ ID NO:2 at the time the claimed invention was made.